<DOC>
	<DOCNO>NCT01383434</DOCNO>
	<brief_summary>Patients severe , refractory aplastic anemia severe , life threaten disease bone marrow . Refractory disease mean disease come back respond receive one immunosuppressive treatment . High dose chemotherapy follow bone marrow transplantation ( BMT ) use treat blood disease like aplastic anemia complication Graft v Host disease ( GVHD ) graft failure limit survival patient . Another study do Johns Hopkins show patient disease ( blood cancer ) immunosuppressive drug give BMT decrease often patient complication GVHD engraftment failure . This research do find approach help patient aplastic anemia fail treatment well outcomes .</brief_summary>
	<brief_title>Bone Marrow Transplant Trial Patients With Refractory Severe Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patients refractory relapse SAA follow treatment one immunosuppressive regimen . Age 6 month 70 year Patients must meet medical criterion myeloablative BMT Patients parents/guardians donor must able sign consent form . Patients must geographically accessible willing participate stage treatment . Poor cardiac function : leave ventricular ejection fraction &lt; 45 % determined MUGA ECHO . Poor pulmonary function : FEV1 FVC &lt; 50 % predict . Poor renal function Positive leukocytotoxic crossmatch Women childbearing potential currently pregnant ( Î’HCG+ ) practice adequate contraception Uncontrolled viral , bacterial , fungal infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>